STOCK TITAN

Clarivate Plc - CLVT STOCK NEWS

Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.

Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.

Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.

Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.

Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.

The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.

Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.

For more information about Clarivate, its products, and services, visit www.clarivate.com.

Rhea-AI Summary

Clarivate (NYSE: CLVT) reported Q3 2024 financial results showing revenue decline to $622.2 million, down 3.9%, with organic revenues decreasing 2.6%. The company posted a net loss of $65.6 million ($0.09 per diluted share). Adjusted EBITDA fell 6.0% to $264.4 million, with margins declining 100 basis points to 42.5%. Free cash flow improved to $126.3 million. For the nine months ended September 30, revenues declined 2.6% to $1,893.7 million, with a net loss of $444.9 million. The CEO acknowledged unsatisfactory results, citing overdependence on fluctuating transactional revenue and announced a Value Creation Plan to improve performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.16%
Tags
-
Rhea-AI Summary

Silverchair, a Thompson Street Capital Partners portfolio company, has announced an agreement to acquire ScholarOne from Clarivate Plc (NYSE:CLVT). Silverchair provides software and services to STM content publishers, serving over 400 publishers through its content management system. ScholarOne, specializing in manuscript submission and peer review management, serves more than 600 publishers and processes over three million manuscripts annually. The acquisition aims to create a comprehensive solution for scholarly publishing and is expected to close in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will release its third quarter 2024 financial results on Wednesday, November 6, 2024, before the market opens. The company will also host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.

Investors and interested parties can access the press release, earnings supplement, and accompanying financial information on the Clarivate investor website at https://ir.clarivate.com. The webcast will be open to all interested parties and may include forward-looking information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has announced the success of its annual Citation Laureates™ program, accurately predicting eight Nobel Prize 2024 recipients. The program, powered by the Web of Science Core Collection™ citation index, combines citation analysis with expert insights to identify potential Nobel laureates. Since 2002, 83 out of 441 Citation Laureates have received a Nobel Prize, with successful forecasts every year since 2007.

Notable predictions include David Baker, Demis Hassabis, and John M. Jumper for the Nobel in Chemistry, Victor Ambros and Gary Ruvkun for Physiology or Medicine, and Daron Acemoglu, Simon Johnson, and James A. Robinson for Economic Sciences. The success of the program highlights the value of Clarivate's data-driven approach in identifying researchers with exceptional citation records and potential Nobel honors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary

Clarivate and Abiquifi have announced the agenda for the 2nd annual Summit LATAM, scheduled for October 7, 2024, in Milan. The event, preceding CPHI Milan, will focus on AI, data, strategic partnerships, and innovation opportunities in the Latin American pharmaceutical market, valued at $98 billion with projected growth of 10.1%.

Key sessions will cover topics such as driving growth with data and AI, competitive partnerships, regulatory guidelines, and local API production. The summit aims to address challenges and uncover opportunities in the region's evolving pharmaceutical landscape. Industry leaders from Clarivate, Abiquifi, Knight Therapeutics, EMS, Gene Pharm, Libbs Farmacêutica, ANVISA, Nortec, Emcure Mexico, and Globe Química will share insights and perspectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
partnership
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has unveiled a comprehensive framework for evaluating the societal impact of research. The approach, detailed in a new report by the Institute for Scientific Information (ISI)™, addresses the growing demand for demonstrating the benefits of R&D investments across various sectors of society.

The framework categorizes societal needs into eight facets: Political & Policy, Legal & Governance, Economic, Human Capital, Medical, Social & Cultural, Technological and Environmental. It aims to balance qualitative and quantitative approaches, extending beyond traditional quantitative indicators.

To address the challenge of long timeframes between research discovery and societal application, the framework incorporates both lagging and leading indicators. This new approach will be integrated into the upcoming Web of Science Research Intelligence™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has released a new report titled 'Excellence in IP Operations' based on a global survey of 184 IP professionals. The report highlights key challenges and trends shaping intellectual property (IP) operations, focusing on strategy alignment, resource allocation, technology enablement, and AI adoption.

Key findings include:

  • 65% of corporate respondents with clear KPIs reported alignment between IP and business strategies
  • Well-managed operational processes correlate with greater strategic alignment and efficient staff use
  • 83% of respondents spending over half their time on unrelated tasks were not using AI in their IP department
  • 64% of respondents dissatisfied with their technology setup spent more time on tasks outside their primary role

The report emphasizes the importance of aligning KPIs with business goals, effective process management, closing the AI adoption gap, and leveraging technology for efficiency in IP operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has announced a strategic partnership with Relatable Healthcare to enhance medtech sales contracting processes. This collaboration integrates Clarivate's comprehensive competitive intelligence into Relatable's Product Relationship Management (PRM) platform, providing medtech companies with a single source of truth for product information and competitive data.

The partnership aims to empower clients to make informed pricing decisions, streamline sales contracting, and improve contract compliance. It addresses the challenges faced by medical device and supply companies in communicating product value and offering consultative insights in a cost-constrained healthcare environment.

By combining Clarivate's deep product-level market knowledge with Relatable Healthcare's enterprise software, the partnership equips medtech companies with tools to win new business and drive contract compliance more efficiently, particularly when serving Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), and various healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
partnership
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has unveiled its Citation Laureates™ 2024 list, recognizing 22 exceptional scientists and economists from six countries whose work is considered of Nobel stature. These individuals have made significant contributions in areas such as clean energy, nanotechnology, 3D protein structures, and quantum computing. The list includes 11 researchers from the US, six from the UK, two from Switzerland, and one each from Germany, Israel, and Japan.

Clarivate's Institute for Scientific Information (ISI)™ has successfully identified 75 Citation Laureates prior to their Nobel success. The selection process is based on publication and citation data from the Web of Science™, focusing on authors whose papers have been cited more than 2,000 times. This year's laureates span fields including Physiology or Medicine, Physics, Chemistry, and Economics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has announced the full agenda for the 15th annual Clarivate Pharmavision India conference, scheduled for September 25-26, 2024, in Ahmedabad and Hyderabad. The event focuses on improving patient outcomes and building resilience in the healthcare ecosystem. Key topics include AI in healthcare, cell and gene therapy, and market access.

The conference aims to address challenges such as healthcare affordability and access in India. Industry leaders will discuss strategies for patient-centric innovation, R&D, generics, biosimilars, and healthcare manufacturing. Notable sessions will cover topics like balancing generics and innovation, AI's role in healthcare, and addressing barriers to cell and gene therapy integration in India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none

FAQ

What is the current stock price of Clarivate Plc (CLVT)?

The current stock price of Clarivate Plc (CLVT) is $5.11 as of January 6, 2025.

What is the market cap of Clarivate Plc (CLVT)?

The market cap of Clarivate Plc (CLVT) is approximately 3.7B.

What does Clarivate do?

Clarivate provides transformative intelligence, offering enriched data, insights, and analytics across sectors like Academia & Government, Intellectual Property, and Life Sciences & Healthcare.

What are some of Clarivate’s trusted brands?

Some of Clarivate’s most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™.

Where is Clarivate headquartered?

Clarivate is headquartered in London and operates in over 100 countries.

How did Clarivate become an independent company?

Clarivate was formerly part of Thomson Reuters and became an independent company in 2016 after being sold to private equity.

When did Clarivate go public?

Clarivate went public on the New York Stock Exchange in 2019.

What recent advancements has Clarivate made in the field of cancer treatment?

Clarivate has been exploring the rapid pipeline growth and clinical trials in CAR T-cell therapies, particularly in China, as part of their commitment to innovative cancer treatments.

What is Cortellis CMC Intelligence™?

Cortellis CMC Intelligence™ is a solution that helps pharmaceutical, biotech, and generics companies streamline regulatory tracking and optimize lifecycle management for small molecules and biologics.

What is Epidemiology Intelligence™?

Epidemiology Intelligence™ combines epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics.

What is the purpose of the Trademark Watch Analyzer?

The Trademark Watch Analyzer is an AI-enhanced trademark protection solution that provides faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

How does Clarivate enhance patient outcomes with HealthWise Data?

Clarivate's partnership with HealthWise Data integrates Social Determinants of Health (SDoH) attributes into its Real-World Data repository, offering nuanced patient insights to enhance outcomes and healthcare equity.
Clarivate Plc

NYSE:CLVT

CLVT Rankings

CLVT Stock Data

3.68B
389.32M
15.85%
92.78%
6.54%
Information Technology Services
Services-computer Processing & Data Preparation
Link
United States of America
ST. HELIER